RRx-001 protects against cisplatin-induced toxicities
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-017-2416-4
Abstract: PurposeRRx-001, a minimally toxic tumor-associated macrophage and neutrophil-repolarizing agent, is under investigation in Phase II clinical trials as a sensitizer/resensitizer to cisplatin and carboplatin. On the basis of anecdotal clinical observations of improved platinum tolerability… read more here.
Keywords: cisplatin; induced toxicities; rrx 001; 001 protects ... See more keywords